PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31748715-0	2020	Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression.	bexarotene	47-57	nuclear receptor subfamily 2 group C member 2	Homo sapiens	10-13
31748715-8	2020	Together, these results suggest that targeting this newly identified TR4/lincRNA-p21/HIF-1alpha/VEGF-A signaling with Bex, an FDA-approved drug, may increase the DTX chemo-sensitivity to better suppress the mCRPC progression.	bexarotene	118-121	nuclear receptor subfamily 2 group C member 2	Homo sapiens	69-72
31748715-6	2020	Targeting TR4 with an antagonist bexarotene (Bex, a derivative of retinoid) suppressed the TR4 transactivation with increased DTX chemo-sensitivity.	bexarotene	33-43	nuclear receptor subfamily 2 group C member 2	Homo sapiens	10-13
31748715-8	2020	Together, these results suggest that targeting this newly identified TR4/lincRNA-p21/HIF-1alpha/VEGF-A signaling with Bex, an FDA-approved drug, may increase the DTX chemo-sensitivity to better suppress the mCRPC progression.	bexarotene	118-121	tumor protein p53 pathway corepressor 1	Homo sapiens	73-84
31748715-6	2020	Targeting TR4 with an antagonist bexarotene (Bex, a derivative of retinoid) suppressed the TR4 transactivation with increased DTX chemo-sensitivity.	bexarotene	33-43	nuclear receptor subfamily 2 group C member 2	Homo sapiens	91-94
31748715-6	2020	Targeting TR4 with an antagonist bexarotene (Bex, a derivative of retinoid) suppressed the TR4 transactivation with increased DTX chemo-sensitivity.	bexarotene	45-48	nuclear receptor subfamily 2 group C member 2	Homo sapiens	10-13
31748715-8	2020	Together, these results suggest that targeting this newly identified TR4/lincRNA-p21/HIF-1alpha/VEGF-A signaling with Bex, an FDA-approved drug, may increase the DTX chemo-sensitivity to better suppress the mCRPC progression.	bexarotene	118-121	hypoxia inducible factor 1 subunit alpha	Homo sapiens	85-95
31748715-6	2020	Targeting TR4 with an antagonist bexarotene (Bex, a derivative of retinoid) suppressed the TR4 transactivation with increased DTX chemo-sensitivity.	bexarotene	45-48	nuclear receptor subfamily 2 group C member 2	Homo sapiens	91-94
31826730-7	2020	Results- Bexarotene increased macrophage expression of phagocytosis receptors and erythrophagocytosis and reduced macrophage TNF (tumor necrosis factor) production in vitro.	bexarotene	9-19	tumor necrosis factor	Mus musculus	125-128
31748715-8	2020	Together, these results suggest that targeting this newly identified TR4/lincRNA-p21/HIF-1alpha/VEGF-A signaling with Bex, an FDA-approved drug, may increase the DTX chemo-sensitivity to better suppress the mCRPC progression.	bexarotene	118-121	vascular endothelial growth factor A	Homo sapiens	96-102
31826730-7	2020	Results- Bexarotene increased macrophage expression of phagocytosis receptors and erythrophagocytosis and reduced macrophage TNF (tumor necrosis factor) production in vitro.	bexarotene	9-19	tumor necrosis factor	Mus musculus	130-151
31576145-0	2019	Synergistic effect of a retinoid X receptor-selective ligand bexarotene and docetaxel in prostate cancer.	bexarotene	61-71	retinoid X receptor alpha	Homo sapiens	24-43
31680194-0	2019	Bexarotene Attenuates Focal Cerebral Ischemia-Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway.	bexarotene	0-10	mitogen-activated protein kinase 8	Mus musculus	88-91
31680194-0	2019	Bexarotene Attenuates Focal Cerebral Ischemia-Reperfusion Injury via the Suppression of JNK/Caspase-3 Signaling Pathway.	bexarotene	0-10	caspase 3	Mus musculus	92-101
31680194-2	2019	Bexarotene, a selective agonist of the retinoid X receptor, has been reported to enhance markedly the expression of APOE.	bexarotene	0-10	apolipoprotein E	Mus musculus	116-120
31576145-4	2019	Results: When mitotic slippage happens, BEX can synergistically strengthen the anti-proliferation of DTX in a way of significantly down-regulating cyclinB1 and CDK1 expression, and then arresting cells in G2 phase.	bexarotene	40-43	cyclin B1	Homo sapiens	147-155
31576145-4	2019	Results: When mitotic slippage happens, BEX can synergistically strengthen the anti-proliferation of DTX in a way of significantly down-regulating cyclinB1 and CDK1 expression, and then arresting cells in G2 phase.	bexarotene	40-43	cyclin dependent kinase 1	Homo sapiens	160-164
31616630-0	2019	Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma.	bexarotene	0-10	C-C motif chemokine ligand 22	Homo sapiens	33-38
31616630-4	2019	Intraperitoneal injection of bexarotene significantly decreased expressions of CCL22, CXCL5, CXCL10, and p19 in the tumor microenvironment.	bexarotene	29-39	C-C motif chemokine ligand 22	Homo sapiens	79-84
31616630-4	2019	Intraperitoneal injection of bexarotene significantly decreased expressions of CCL22, CXCL5, CXCL10, and p19 in the tumor microenvironment.	bexarotene	29-39	C-X-C motif chemokine ligand 5	Homo sapiens	86-91
31616630-4	2019	Intraperitoneal injection of bexarotene significantly decreased expressions of CCL22, CXCL5, CXCL10, and p19 in the tumor microenvironment.	bexarotene	29-39	C-X-C motif chemokine ligand 10	Homo sapiens	93-99
31616630-4	2019	Intraperitoneal injection of bexarotene significantly decreased expressions of CCL22, CXCL5, CXCL10, and p19 in the tumor microenvironment.	bexarotene	29-39	interleukin 23 subunit alpha	Homo sapiens	105-108
31616630-6	2019	Next, we evaluated serum levels of CCL22, CXCL5, and CXCL10 in CTCL patients treated with bexarotene.	bexarotene	90-100	C-X-C motif chemokine ligand 10	Homo sapiens	53-59
31616630-7	2019	Serum levels of CCL22 were significantly decreased in 80% of CTCL patients who responded to bexarotene therapy.	bexarotene	92-102	C-C motif chemokine ligand 22	Homo sapiens	16-21
31616630-9	2019	Moreover, bexarotene decreased the production of CCL22 by M2 macrophages generated from monocytes in vitro.	bexarotene	10-20	C-C motif chemokine ligand 22	Homo sapiens	49-54
31616630-10	2019	Our findings suggest that the clinical benefits of bexarotene are partially attributable to suppressive effects on the production of CCL22 by M2-polarized tumor-associated macrophages.	bexarotene	51-61	C-C motif chemokine ligand 22	Homo sapiens	133-138